Drug Profile
Alferminogene tadenovec - Angionetics
Alternative Names: Ad5-FGF4; AdFGF-4; AGT-MI; Angiogenic gene therapy; Cardionovo; FGF-4 angiogenic DNA - Taxus Cardium Pharmaceuticals; FGF-4 gene therapy; Fibroblast growth factor-4 gene therapy - Taxus Cardium Pharmaceuticals; Generx; Generx microvascular therapy; mdFGF-4; mdFGF-4 - Taxus Cardium PharmaceuticalsLatest Information Update: 10 Feb 2017
Price :
$50
*
At a glance
- Originator Cardium Therapeutics
- Developer Angionetics; Gene Biotherapeutics; Taxus Cardium Pharmaceuticals Group
- Class Gene therapies; Growth factors; Ischaemic heart disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Coronary artery disease; Myocardial ischaemia
- Discontinued Heart failure
Most Recent Events
- 07 Feb 2017 Alferminogene tadenovec receives Fast Track designation for Coronary artery disease [Intracoronary,Infusion] in USA
- 12 Sep 2016 The U.S. FDA Center for Biologics Evaluation and Research approves alferminogene tadenovec for the phase III AFFIRM study in Coronary artery disease and Myocardial ischaemia
- 11 Jul 2016 Alferminogene tadenovec licensed to an affiliated entity of Huapont Life Sciences in China